OR WAIT 15 SECS
Covance Inc. (NYSE:CVD), a provider of drug development services, today announced that its clinical pharmacology services were recognized for outstanding customer service by Eli Lilly and Company.
Covance Recognized for Outstanding
Customer Service by Eli Lilly and Company
-Covance Clinical Research Unit in Leeds receives Lilly's 2008 Global Supplier Award-
PRINCETON, NJ, July 31, 2008 - Covance Inc. (NYSE:CVD), a leading provider of drug development services, today announced that its clinical pharmacology services were recognized for outstanding customer service by Eli Lilly and Company. Covance's clinical research unit based in Leeds, UK received Lilly's 2008 Global Supplier Award, which acknowledges and encourages the contributions of key suppliers that contribute the best in innovation and technology towards Lilly's success. Covance is one of a select group of suppliers to Lilly that has demonstrated its commitment to helping the company meet its corporate objectives. Covance was judged by a committee of Lilly representatives on criteria including supplier relationship management, quality, speed, service, cost reduction, and supplier diversity. "We are honored to receive such a high level of recognition from one of the world's most prominent pharmaceutical companies," said Mary Westrick, Covance Global Vice President and General Manager of Clinical Pharmacology. "Covance is proud that our pharmaceutical clients consider us integral partners in their important development of new therapies and cures." Covance's clinical pharmacology service offering evaluates the safety and efficacy of potential new drugs in humans, including the conduct of first-in-human trials. Covance has pioneered many of the specialized services in its diversified portfolio of drug development services and that uniquely positions the company as a valued partner in helping to progress compounds from preclinical to proof-of-concept studies.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and greater than 9,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission. Covance and the Covance are registered service marks of Covance in the United States and other countries.